Jasper Therapeutics Inc (JSPR)
22.98
+0.14
(+0.59%)
USD |
NASDAQ |
May 17, 16:00
22.98
0.00 (0.00%)
After-Hours: 20:00
Jasper Therapeutics Cash from Financing (TTM): 46.81M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 46.81M |
December 31, 2023 | 100.97M |
September 30, 2023 | 101.27M |
June 30, 2023 | 101.24M |
March 31, 2023 | 101.55M |
Date | Value |
---|---|
December 31, 2022 | 0.055M |
September 30, 2022 | -0.882M |
June 30, 2022 | 90.84M |
March 31, 2022 | 90.23M |
December 31, 2021 | 100.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.882M
Minimum
Sep 2022
101.55M
Maximum
Mar 2023
73.31M
Average
95.91M
Median
Cash from Financing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 1.313M |
Palatin Technologies Inc | 14.71M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.68M |
Oragenics Inc | 0.2839M |